| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 14, 2023 | ELAN Elanco Animal Health Inc | Hoover R David50 | Director | Buy | 10,000 | $9.50 | $95,038.00 | +3.2% | -0.4% | +69.3% | |
| Mar 13, 2023 | PRGO Perrigo Co Plc | Farrington Thomas | EVP And CIO | Sell | 3,723 | $35.57 | $132,434.63 | -38.9% | -6.4% | -13.4% | |
| Mar 13, 2023 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 16,000 | $227.84 | $3,645,485.60 | -27.1% | +1.4% | +9.9% | |
| Mar 10, 2023 | PRGO Perrigo Co Plc | Dillard James E III | EVP &President Csca | Sell | 9,000 | $35.70 | $321,309.00 | -26.4% | -6.1% | -15.6% | |
| Mar 10, 2023 | LLY Eli Lilly & Co | Weems Alonzo | EVP, Erm &Ceco | Sell | 1,000 | $318.85 | $318,850.00 | -10.1% | +41.5% | +141.9% | |
| Mar 10, 2023 | ELAN Elanco Animal Health Inc | Simmons Jeffrey N52 | President, CEO And Director | Buy | 15,000 | $9.60 | $143,971.50 | +50.0% | -2.3% | +71.9% | |
| Mar 9, 2023 | VRNO Verano Holdings Corp. | Miles Aaron Nathaniel | Chief Investment Officer | Sell | 1,160 | $3.14 | $3,637.06 | -2.1% | - | - | |
| Mar 9, 2023 | VRNO Verano Holdings Corp. | Spreckman David | EVP, Marketing | Sell | 248 | $3.14 | $777.58 | -7.2% | - | - | |
| Mar 9, 2023 | VRNO Verano Holdings Corp. | Archos George Peter | Chief Executive Officer | Sell | 5,049 | $3.14 | $15,830.63 | -0.8% | - | - | |
| Mar 9, 2023 | VRNO Verano Holdings Corp. | Weiss Darren Henry | COO, CLO, GC And Secretary | Sell | 6,048 | $3.14 | $18,962.90 | -1.0% | - | - | |
| Mar 9, 2023 | TSNDF Terrascend Corp. | Swartzman Lisa | Director | Sell | 27,194 | $1.58 | $42,884.94 | -14.3% | - | - | |
| Mar 9, 2023 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 16,000 | $224.72 | $3,595,459.47 | -20.3% | -2.0% | +7.9% | |
| Mar 8, 2023 | PRGO Perrigo Co Plc | Janish Ronald Craig61 | EVP, Gbl Ops &Sc &CTO | Sell | 4,500 | $36.92 | $166,133.25 | -18.2% | -9.5% | -19.9% | |
| Mar 8, 2023 | LNTH Lantheus Holdings, Inc. | Heino Mary Anne50 | President &CEO | Sell | 10,064 | $74.70 | $751,793.42 | -0.7% | +19.2% | -16.8% | |
| Mar 8, 2023 | HIMS Hims & Hers Health, Inc. | Wells David B51 | Director | Sell | 100,000 | $9.77 | $976,540.00 | -22.7% | -7.0% | +45.2% | |
| Mar 7, 2023 | ESPR Esperion Therapeutics, Inc. | Koenig Sheldon L.60 | President And CEO | Sell | 5,441 | $5.06 | $27,509.70 | -2.7% | -72.5% | -49.8% | |
| Mar 7, 2023 | ESPR Esperion Therapeutics, Inc. | Warren Eric60 | Chief Commercial Officer | Sell | 5,090 | $5.06 | $25,729.95 | -9.5% | -72.5% | -49.8% | |
| Mar 7, 2023 | ESPR Esperion Therapeutics, Inc. | Foody Joanne M.73 | Chief Medical Officer | Sell | 3,884 | $5.07 | $19,672.46 | -3.6% | -72.5% | -49.8% | |
| Mar 7, 2023 | LNTH Lantheus Holdings, Inc. | Marshall Robert J. Jr.53 | CFO And Treasurer | Sell | 25,441 | $72.48 | $1,844,048.82 | -8.6% | +21.0% | -14.4% | |
| Mar 7, 2023 | LNTH Lantheus Holdings, Inc. | Montagut Etienne51 | Chief Business Officer | Sell | 17,710 | $72.48 | $1,283,618.19 | -9.0% | +21.0% | -14.4% | |
| Mar 7, 2023 | TEVA Teva Pharmaceutical Industries Ltd | Stark David Matthew53 | Exec. VP Chief Legal Officer | Sell | 65,966 | $9.55 | $630,215.82 | -54.3% | -23.6% | +43.3% | |
| Mar 7, 2023 | TEVA Teva Pharmaceutical Industries Ltd | Daniell Richard | Exec. VP, European Commercial | Sell | 72,009 | $9.55 | $687,948.66 | -27.1% | -23.6% | +43.3% | |
| Mar 7, 2023 | TEVA Teva Pharmaceutical Industries Ltd | Drape Eric51 | Executive VP Global Operations | Sell | 6,265 | $9.55 | $59,853.49 | -1.8% | -23.6% | +43.3% | |
| Mar 7, 2023 | LNTH Lantheus Holdings, Inc. | Sabens Andrea47 | Chief Accounting Officer | Sell | 8,655 | $72.52 | $627,628.81 | -6.4% | +21.0% | -14.4% | |
| Mar 7, 2023 | TEVA Teva Pharmaceutical Industries Ltd | Dethlefs Sven | EVP, North America Commercial | Sell | 77,421 | $9.55 | $739,653.01 | -16.6% | -23.6% | +43.3% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.